A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer

Oncology Reports

Volumn 15, Issue 1, 2006, Pages 123-127

  Govindan, Ramaswamy ^a   Lim, Wan Teck ^c   Arquette, Matthew A ^a   Goodner, Sherry A ^a   Fears, Carole L ^a   Mortimer, Joanne E ^b   Fracasso, Paula M ^a  

^a USA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Nacional Cancer Center   (Singapore)

Author keywords

Advanced non small cell lung cancer; Docetaxel; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DRUG DERIVATIVE; NAVELBINE; TAXOID; VINBLASTINE;

AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 33644877356     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.1.123     Document Type: Article

References (30)

1. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995.
2. Breathnach OS, Freidlin B, Conley B, et al: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19: 1734-1742, 2001. (Pubitemid 32230875)
3. Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17: 3188-3194, 1999. (Pubitemid 29470650)
4. Spiro SG, Rudd RM, Souhami RL, et al: Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59: 828-836, 2004. (Pubitemid 39389621)
5. Thongprasert S, Sanguanmitra P, Juthapan W and Clinch J: Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 24: 17-24, 1999. (Pubitemid 29241813)
6. Helsing M, Bergman B, Thaning L and Hero U: Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 34: 1036-1044, 1998. (Pubitemid 28308344)
7. Miller VA, Rigas JR, Francis PA, et al : Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75: 968-972, 1995.
8. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13: 645-651, 1995.
9. Shepherd FA, Dancey J, Ramlau R, et al : Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000. (Pubitemid 30324363)
10. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18: 2354-2362, 2000. (Pubitemid 30415821)
11. Fossella F, Pereira JR, von Pawel J, et al: Randomized, multi-national, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016-3024, 2003. (Pubitemid 46606280)
12. Crawford J, O'Rourke M, Schiller JH, et al: Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 14: 2774-2784, 1996. (Pubitemid 26329664)
13. Furuse K, Fukuoka M, Kuba M, et al : Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group. Ann Oncol 7: 815-820, 1996. (Pubitemid 26345872)
14. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367, 1994.
15. Aoe K, Kiura K, Ueoka H, et al : Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res 19: 291-299, 1999. (Pubitemid 29168252)
16. Bissery MC, Vrignaud P and Lavelle F: Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Semin Oncol 22: 3-16, 1995. (Pubitemid 26001348)
17. Budman DR, Calabro A, Wang LG, et al: Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. Cancer Invest 18: 695-701, 2000.
18. Photiou A, Shah P, Leong LK, Moss J and Retsas S: In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur J Cancer 33: 463-470, 1997. (Pubitemid 27168075)
19. Sanchez JM, Balana C, Font A, et al: Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Lung Cancer 38: 309-315, 2002. (Pubitemid 35341807)
20. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981. (Pubitemid 11167383)
21. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002. (Pubitemid 34438899)
22. Bennouna J, Monnier A, Rivi A, et al : A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer. Eur J Cancer 36: 1107-1112, 2000. (Pubitemid 30330908)
23. Kourousis C, Androulakis N, Kakolyris S, et al : First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine. Cancer 83: 2083-2090, 1998. (Pubitemid 28525389)
24. Miller VA, Krug LM, Ng KK, et al: Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 18: 1346-1350, 2000. (Pubitemid 30159855)
25. Miller VA, Ng KK, Krug LM, et al: Phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung carcinoma. Cancer 88: 1045-1050, 2000 (Pubitemid 30127664)
26. Leu KM, Kim KM, Larson M and Schiller JH: Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. Lung Cancer 34: 105-113, 2001. (Pubitemid 32824130)
27. Hainsworth JD, Burris HA 3rd, Billings FT 3rd, Bradof JE, Baker M and Greco FA: Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network. Cancer 92: 2391-2398, 2001. (Pubitemid 33029084)
28. Kelly K: The benefits of achieving stable disease in advanced lung cancer. Oncology 17: 957-970, 2003.
29. Smith IE, O'Brien ME, Talbot DC, et al: Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19: 1336-1343, 2001. (Pubitemid 32202538)
30. Socinski MA, Schell MJ, Peterman A, et al : Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20: 1335-1343, 2002. (Pubitemid 34182817)